BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in Cystic Fibrosis. Journal of Cystic Fibrosis 2017;16:S70-8. [DOI: 10.1016/j.jcf.2017.06.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Hayee B, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings P, Macedo P, Perrin F, Whelan K, Elston C. A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. United European Gastroenterol J 2019;7:881-8. [PMID: 31428412 DOI: 10.1177/2050640619841545] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
2 McHugh DR, Steele MS, Valerio DM, Miron A, Mann RJ, LePage DF, Conlon RA, Cotton CU, Drumm ML, Hodges CA. A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies. PLoS One. 2018;13:e0199573. [PMID: 29924856 DOI: 10.1371/journal.pone.0199573] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
3 Ng C, Major G, Smyth AR; Cochrane Cystic Fibrosis and Genetic Disorders Group. Dosing regimens for pancreatic enzyme replacement therapy (PERT) in cystic fibrosis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013488] [Reference Citation Analysis]
4 Ng C, Major G, Smyth AR. Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis. Cochrane Database Syst Rev 2021;8:CD013488. [PMID: 34339047 DOI: 10.1002/14651858.CD013488.pub2] [Reference Citation Analysis]
5 Colomba J, Netedu SR, Lehoux-Dubois C, Coriati A, Boudreau V, Tremblay F, Cusi K, Rabasa-Lhoret R, Leey JA. Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis. PLoS One 2019;14:e0219855. [PMID: 31318914 DOI: 10.1371/journal.pone.0219855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Boon M, Claes I, Havermans T, Fornés-Ferrer V, Calvo-Lerma J, Asseiceira I, Bulfamante A, Garriga M, Masip E, Woodcock S, Walet S, Barreto C, Colombo C, Crespo P, Van der Wiel E, Hulst J, Martinez-Barona S, Nobili R, Pereira L, Ruperto M, Vicente S, De Boeck K, Ribes-Koninckx C; MyCyFAPP consortium. Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents. PLoS One 2019;14:e0225004. [PMID: 31860639 DOI: 10.1371/journal.pone.0225004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Lee AJ, Huffmyer JL, Thiele EL, Zeitlin PL, Chatterjee D. The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists. Anesth Analg 2022. [PMID: 35020677 DOI: 10.1213/ANE.0000000000005856] [Reference Citation Analysis]
8 Davies JC, Wainwright CE, Sawicki GS, Higgins MN, Campbell D, Harris C, Panorchan P, Haseltine E, Tian S, Rosenfeld M. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med 2021;203:585-93. [PMID: 33023304 DOI: 10.1164/rccm.202008-3177OC] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
9 Imrei M, Németh D, Szakács Z, Hegyi P, Kiss S, Alizadeh H, Dembrovszky F, Pázmány P, Bajor J, Párniczky A. Increased Prevalence of Celiac Disease in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis. J Pers Med 2021;11:859. [PMID: 34575636 DOI: 10.3390/jpm11090859] [Reference Citation Analysis]
10 Sullivan JS, Mascarenhas MR. Nutrition: Prevention and management of nutritional failure in Cystic Fibrosis. J Cyst Fibros 2017;16 Suppl 2:S87-93. [PMID: 28986026 DOI: 10.1016/j.jcf.2017.07.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
11 Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129-139. [PMID: 30962702 DOI: 10.2147/ceg.s168266] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 10.7] [Reference Citation Analysis]
12 J Burton S, Hachem C, Abraham JM. Luminal Gastrointestinal Manifestations of Cystic Fibrosis. Curr Gastroenterol Rep 2021;23:4. [PMID: 33758994 DOI: 10.1007/s11894-021-00806-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kunovský L, Dítě P, Jabandžiev P, Eid M, Poredská K, Vaculová J, Sochorová D, Janeček P, Tesaříková P, Blaho M, Trna J, Hlavsa J, Kala Z. Causes of Exocrine Pancreatic Insufficiency Other Than Chronic Pancreatitis. J Clin Med 2021;10:5779. [PMID: 34945075 DOI: 10.3390/jcm10245779] [Reference Citation Analysis]
14 Marson FAL. Disease-modifying genetic factors in cystic fibrosis. Curr Opin Pulm Med 2018;24:296-308. [PMID: 29517584 DOI: 10.1097/MCP.0000000000000479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
15 Bass R, Brownell JN, Stallings VA. The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status. Nutrients 2021;13:2907. [PMID: 34578785 DOI: 10.3390/nu13092907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Freedman SD, Wilschanski M, Schwarzenberg SJ. Advancing the GI frontier for patients with CF. J Cyst Fibros 2018;17:1-2. [PMID: 29208346 DOI: 10.1016/j.jcf.2017.11.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 da Silva Filho LVRF, Zampoli M, Cohen-Cymberknoh M, Kabra SK. Cystic fibrosis in low and middle-income countries (LMIC): A view from four different regions of the world. Paediatr Respir Rev 2021;38:37-44. [PMID: 32826173 DOI: 10.1016/j.prrv.2020.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Raun AMT, Brekke G, Mølgaard C, Jaudszus A, Mainz JG, Pressler T, Skov M. Impact of timing of PERT on gastrointestinal symptoms in Danish children and adolescents with CF. Acta Paediatr 2021. [PMID: 34626004 DOI: 10.1111/apa.16143] [Reference Citation Analysis]
19 Kolonko AK, Efing J, González-Espinosa Y, Bangel-Ruland N, van Driessche W, Goycoolea FM, Weber WM. Capsaicin-Loaded Chitosan Nanocapsules for wtCFTR-mRNA Delivery to a Cystic Fibrosis Cell Line. Biomedicines 2020;8:E364. [PMID: 32962254 DOI: 10.3390/biomedicines8090364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Maev IV, Kucheryavyy YA, Andreev DN. Exocrine pancreas insufficiency: clinical significance and approaches to correction from evidence medicine. Terapevticheskii arkhiv 2021;93:509-15. [DOI: 10.26442/00403660.2021.04.200800] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Munce D, Lim M, Akong K. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor. Pediatr Pulmonol 2020;55:3381-3. [PMID: 32910556 DOI: 10.1002/ppul.25065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Butnariu LI, Țarcă E, Cojocaru E, Rusu C, Moisă ȘM, Leon Constantin MM, Gorduza EV, Trandafir LM. Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine. J Clin Med 2021;10:5821. [PMID: 34945117 DOI: 10.3390/jcm10245821] [Reference Citation Analysis]
23 Moryousef J, Kwong J, Kishibe T, Ordon M. Systematic Review of the Prevalence of Kidney Stones in Cystic Fibrosis. J Endourol 2021. [PMID: 33906435 DOI: 10.1089/end.2021.0151] [Reference Citation Analysis]
24 Boon M, Calvo-Lerma J, Claes I, Havermans T, Asseiceira I, Bulfamante A, Garriga M, Masip E, van Schijndel BAM, Fornes V, Barreto C, Colombo C, Crespo P, Vicente S, Janssens H, Hulst J, Witters P, Nobili R, Pereira L, Ruperto M, Van der Wiel E, Mainz JG, De Boeck K, Ribes-Koninckx C. Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis. J Cyst Fibros 2020;19:562-8. [PMID: 32335023 DOI: 10.1016/j.jcf.2020.04.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
25 Amara S, Bourlieu C, Humbert L, Rainteau D, Carrière F. Variations in gastrointestinal lipases, pH and bile acid levels with food intake, age and diseases: Possible impact on oral lipid-based drug delivery systems. Advanced Drug Delivery Reviews 2019;142:3-15. [DOI: 10.1016/j.addr.2019.03.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
26 Bono-Neri F, Romano C, Isedeh A. Cystic Fibrosis: Advancing Along the Continuum. J Pediatr Health Care 2019;33:242-54. [PMID: 30529125 DOI: 10.1016/j.pedhc.2018.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Wright BA, Ketchen NK, Rasmussen LN, Bartels AR, Singh SB. Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients. Pediatr Pulmonol 2021. [PMID: 34859619 DOI: 10.1002/ppul.25781] [Reference Citation Analysis]
28 Gifford AH, Sanville JL, Sathe M, Heltshe SL, Goss CH. Use of proton pump inhibitors is associated with lower hemoglobin levels in people with cystic fibrosis. Pediatr Pulmonol 2021;56:2048-56. [PMID: 33860641 DOI: 10.1002/ppul.25431] [Reference Citation Analysis]
29 Regard L, Martin C, Chassagnon G, Burgel PR. Acute and chronic non-pulmonary complications in adults with cystic fibrosis. Expert Rev Respir Med 2019;13:23-38. [PMID: 30472915 DOI: 10.1080/17476348.2019.1552832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Patterson KD, Kyriacou T, Desai M, Carroll WD, Gilchrist FJ. Factors affecting the growth of infants diagnosed with cystic fibrosis by newborn screening. BMC Pediatr 2019;19:356. [PMID: 31615474 DOI: 10.1186/s12887-019-1727-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
31 Estabrooks S, Brodsky JL. Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators. Int J Mol Sci 2020;21:E452. [PMID: 31936842 DOI: 10.3390/ijms21020452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
32 Soares VEM, do Carmo TIT, Dos Anjos F, Wruck J, de Oliveira Maciel SFV, Bagatini MD, de Resende E Silva DT. Role of inflammation and oxidative stress in tissue damage associated with cystic fibrosis: CAPE as a future therapeutic strategy. Mol Cell Biochem 2021. [PMID: 34529223 DOI: 10.1007/s11010-021-04263-6] [Reference Citation Analysis]
33 Karb DB, Cummings LC. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis. Curr Gastroenterol Rep 2021;23:17. [PMID: 34448955 DOI: 10.1007/s11894-021-00817-2] [Reference Citation Analysis]
34 Brennan AL, Blackman SM. EnVisioning the future: Endocrinology in cystic fibrosis. J Cyst Fibros 2019;18:743-5. [PMID: 31680045 DOI: 10.1016/j.jcf.2019.09.012] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Rickels MR, Norris AW, Hull RL. A tale of two pancreases: exocrine pathology and endocrine dysfunction. Diabetologia 2020;63:2030-9. [PMID: 32894313 DOI: 10.1007/s00125-020-05210-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
36 Ideozu JE, Rangaraj V, Abdala-Valencia H, Zhang X, Kandpal M, Sala MA, Davuluri RV, Levy H. Transcriptional consequences of impaired immune cell responses induced by cystic fibrosis plasma characterized via dual RNA sequencing. BMC Med Genomics 2019;12:66. [PMID: 31118097 DOI: 10.1186/s12920-019-0529-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
37 Dumas MP, Xia S, Bear CE, Ratjen F. Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis. EBioMedicine 2021;73:103660. [PMID: 34740114 DOI: 10.1016/j.ebiom.2021.103660] [Reference Citation Analysis]
38 Tucker SL, Sarr D, Rada B. Granulocytic Myeloid-Derived Suppressor Cells in Cystic Fibrosis. Front Immunol 2021;12:745326. [PMID: 34621276 DOI: 10.3389/fimmu.2021.745326] [Reference Citation Analysis]
39 Kilinc AA, Alishbayli G, Taner HE, Cokugras FC, Cokugras H. Clinical characteristics and genetic analysis of cystic fibrosis transmembrane conductance reseptor-related disease. Pediatr Int 2020;62:629-33. [PMID: 32003094 DOI: 10.1111/ped.14173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
40 Tucker MA, Fox BM, Seigler N, Rodriguez-Miguelez P, Looney J, Thomas J, McKie KT, Forseen C, Davison GW, Harris RA. Endothelial Dysfunction in Cystic Fibrosis: Role of Oxidative Stress. Oxid Med Cell Longev 2019;2019:1629638. [PMID: 31320980 DOI: 10.1155/2019/1629638] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
41 Ensinck M, Mottais A, Detry C, Leal T, Carlon MS. On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis. Front Pharmacol 2021;12:662110. [PMID: 33986686 DOI: 10.3389/fphar.2021.662110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Regard L, Lafoeste H, Martin C, Chassagnon G, Burgel PR. [Ageing with cystic fibrosis: Classical and emerging comorbidities in adults with cystic fibrosis]. Rev Pneumol Clin 2018;74:279-91. [PMID: 30316653 DOI: 10.1016/j.pneumo.2018.09.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
43 Sismanlar Eyuboglu T, Dogru D, Çakır E, Cobanoglu N, Pekcan S, Cinel G, Yalçın E, Kiper N, Sen V, Selimoglu Sen H, Ercan O, Keskin O, Bilgic Eltan S, Alshadfan L, Yazan H, Altıntas DU, Sasihuseyinoglu AS, Sapan N, Cekic S, Cokugraş H, Kılınc AA, Ramaslı Gursoy T, Aslan AT, Bingol A, Başaran AE, Ozdemir A, Kose M, Hangul M, Emiralioglu N, Tugcu G, Yuksel H, Yılmaz O, Orhan F, Gayretli Aydın ZG, Topal E, Tamay Z, Suleyman A, Can D, Bal CM, Caltepe G, Ozcelik U. Clinical features and accompanying findings of Pseudo‐Bartter Syndrome in cystic fibrosis. Pediatr Pulmonol 2020;55:2011-6. [DOI: 10.1002/ppul.24805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
44 Harwood KH, McQuade RM, Jarnicki A, Schneider-Futschik EK. Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis. Int J Mol Sci 2021;22:7606. [PMID: 34299226 DOI: 10.3390/ijms22147606] [Reference Citation Analysis]
45 Ng C, Major G, Smyth AR. A systematic Cochrane Review of the timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis. Paediatr Respir Rev 2021;40:44-5. [PMID: 34635420 DOI: 10.1016/j.prrv.2021.09.002] [Reference Citation Analysis]
46 Nichols AL, Davies JC, Jones D, Carr SB. Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor. Paediatr Respir Rev 2020;35:99-102. [PMID: 32386958 DOI: 10.1016/j.prrv.2020.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]